Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review
ConclusionRTX is a promising therapeutic tool in CTD-related ILD. This systematic review remarks the unmet need of multicenter prospective studies aiming to evaluate the effectiveness of RTX with adequate sample size and study design.
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Clinical Trials | Interstitial Lung Disease | Rituxan | Scleroderma | Study